Associate Professor of Medicine, Director Breast Oncology Clinical Trials, Director Medical Oncology Fellowship Program.
Oncology
Dr. Suleiman A. Massarweh, MD
|
|
Give Review
Dr. Suleiman A. Massarweh practices Oncology. He graduated from Baylor College of Medicine. Suleiman A. Massarweh is a published doctor as well. He has 32 publications published. The latest was: Blastic plasmacytoid dendritic cell neoplasm with extensive cutaneous and central nervous system involvement. He is registered with Medicare and accepts Medicare payments.
Publications
- A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast Cancer after aromatase inhibitor (AI) failure.
- Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast Cancer.
- A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast Cancer.
- Blastic plasmacytoid dendritic cell neoplasm with extensive cutaneous and central Nervous system involvement.
- Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast Cancer disease characteristics: implications for tumor bio...
- Everolimus-Induced Hematologic Changes in Patients With Metastatic Breast Cancer.
- Metastatic angiosarcoma and kasabach-merritt syndrome.
- ErbB3 downregulation enhances luminal Breast tumor response to antiestrogens.
- A prognostic model of early breast Cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation.
- Upregulation of mucin4 in ER-positive/HER2-overexpressing breast Cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
- Pathologic changes in breast Cancer after anti-estrogen therapy.
- Everolimus in HR-positive advanced breast Cancer.
- Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.
- Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast Cancer.
- Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast Cancer.
- Erythroblast island.
- Breast Cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
- HIV-related Hodgkin's disease with central Nervous system involvement and association with Epstein-Barr virus.
- Small-cell Cancers, and an unusual reaction to chemotherapy. Case 2. Synchronous renal cell carcinoma and limited-stage small-cell lung Cancer.
- Prevalence of hormone receptors and HER2/neu in breast Cancer cases in Jordan.
- Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast Cancer.
- Resistance to endocrine therapy in breast Cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
- Unraveling the mechanisms of endocrine resistance in breast Cancer: new therapeutic opportunities.
- Treatment of human epidermal growth factor receptor 2-overexpressing breast Cancer xenografts with multiagent HER-targeted therapy.
- Tamoxifen resistance in Breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
- Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of Breast tumor xenografts.
- Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing Breast tumor xenografts.
- Resolution of extensive leptomeningeal metastasis and clinical spinal cord compression from breast Cancer using weekly docetaxel chemotherapy.
- Images in clinical medicine. Hypertrophic pulmonary osteoarthropathy and tripe palms.
- Unusual sites of malignancy: case 3. Solitary splenic metastasis in lung Cancer with spontaneous rupture.
- Advanced concepts in estrogen receptor biology and breast Cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Schools
University Of Jordan Medical School
Baylor College Of Med
Methodist Hospital The
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Baylor College of Medicine -
University of Jordan Faculty of Medicine
Hospital
-
Stanford Health Care
Drug Facts
| NPI NUMBER | 1972619708 | |
| NPPES Provider LastName | MASSARWEH | |
| NPPES Provider FirstName | SULEIMAN | |
| NPPES Provider ZIPCode | 405360093 | |
| NPPES Provider State | KY | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 463.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 57.0 | |
| Percent Opioid Claims | 12.31 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1972619708 |
| Last Name Of The Provider | MASSARWEH |
| First Name Of The Provider | SULEIMAN |
| View All |
Similar Doctors
|
|
Dr. Julie A. Ribes, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shams A. Shakil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kent E. Taylor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monty S. Metcalfe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan E. Liddle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arvinda Padmanabhan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lowell B. Anthony, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Aruna Arekapudi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elvis S. Donaldson Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam D. Lye, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John J. Rinehart, MD |
|
|
Dr. Mara D. Chambers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory P. Monohan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John L. Villano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Jeremy D. Hart |